Sumitomo Mitsui Trust Holdings, Inc. Nurix Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $168 Billion
- Q3 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 1,557,479 shares of NRIX stock, worth $19.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,557,479
Previous 1,391,638
11.92%
Holding current value
$19.9 Million
Previous $15.9 Million
9.21%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding NRIX
# of Institutions
175Shares Held
79.5MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$87.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$77.5 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$57.1 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$50.5 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$49.6 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $603M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...